Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Biotechnology

Healthcare
$33.11 -1.81%

-$0.61 today

Market cap
$1.94B
Beta
0.97
P/E (TTM)
13.2
EPS (TTM)
$2.52
52W Low $25.52High $40.87

Volume 0.57M

Average 0.82M

HRMY Debt Repayment

Cash used to repay borrowings during the period.

Harmony Biosciences Holdings, Inc.NASDAQ: HRMY

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment growth accelerates

Q2 FY2026 debt repayment of $5M (cash outflow) rose 33.3% year over year, ahead of the +25.0% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +101.0% a year.

Context

  • Debt repayment amounted to 1.9% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Debt repayment grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +33.3% holds above the trailing-twelve-month pace of +25.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$5M+0.0% QoQ
Last fiscal yearDec 2025
-$16.25M+8.3% YoY
LTMJun 2026
-$18.75M+25.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.3%——
1 year+8.3%——
3-year CAGR+101.0%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(16.25M) USD
Year-over-year change
-8.3%

Debt Repayment vs competitors

How HRMY compares with its peers on the latest reported figures

  • HRMY's LTM Jun 2026 debt repayment of $18.75M is the largest of the 4 companies compared; the peer median is $0.
  • Debt repayment amounts to 2.0% of revenue for HRMY.
HRMY Competitors Peer median
Debt Repayment for HRMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 2026$18.75M +25.0%+101.0%2.0%
CMPSCOMPASS Pathways plcLTM Mar 2026$18.55M ———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$0 ———
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 ———
APMDApnimed, Inc.—— ———
Peer median (excluding HRMY) $0———

Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income34.6M181.47M128.85M145.49M158.69M
Depreciation & Amortization18.84M23.39M24.36M24.11M25.34M
Deferred Income Tax00(13.42M)(29.3M)0
Stock-Based Compensation16.11M26.91M31.71M42.6M44.9M
Change in Working Capital2.19M(6.89M)35.04M(7.32M)91.82M
Accounts Receivables(12.67M)(19.9M)(19.4M)(8.89M)(13.75M)
Inventory(609K)135K(1.07M)(1.84M)1.84M
Accounts Payables008.95M(5.38M)3.95M
Other Working Capital15.46M12.87M46.55M8.79M99.78M
Other Non-Cash Items26.83M(80.4M)12.85M44.23M27.47M
Operating Cash Flow98.56M144.47M219.39M219.82M348.2M
Capital Expenditures(298K)(172K)(312K)(1.15M)(310K)
Acquisitions (Net)00(36.97M)(33.07M)0
Purchases of Investments00(127.47M)(105.29M)(86.15M)
Sales of Investments00118.31M98.53M81.06M
Other Investing Activities(100M)(141.66M)0(26.5M)(15M)
Investing Cash Flow(100.3M)(141.83M)(46.44M)(67.48M)(39.65M)
Debt Repayment(500K)(2M)(1.25M)(15M)(16.25M)
Common Stock Issued0006.5M10.21M
Common Stock Repurchased00(100M)00
Dividends Paid00000
Other Financing Activities7.92M8.84M(3.79M)(2.5M)(3M)
Financing Cash Flow7.42M6.84M(105.55M)(11M)(9.05M)
Effect of Forex Changes00000
Net Change in Cash5.68M9.48M67.4M141.34M299.5M
Free Cash Flow98.26M144.29M219.08M218.67M347.89M

Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

Intrinsic Alpha fair value

Locked

Current Price

$33.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.